N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in combination with naltrexone in methamphetamine dependence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Acetylcysteine; Methamphetamine; N-monoacetylcystine; Naltrexone

Criteria

Inclusion Criteria:

1. men and women age 18-65

2. current DSM-IV methamphetamine dependence.

Exclusion Criteria:

1. unstable medical illness

2. history of seizures

3. myocardial infarction within 6 months

4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential

5. any thoughts of suicide

6. lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder

7. previous treatment with N-Acetyl Cysteine or naltrexone

8. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

9. abnormal liver function tests at screening

10. diagnosis of asthma

11. current use of opiates.